Mutagenic and carcinogenic potency determinations for NDMA support the cumulative dose assumption underpinning the less-than-lifetime Threshold of Toxicological Concern.

5 d) visually, there appears to be a slight trend of increasing BMDs ( i . e . , lower potency estimations) with increasing exposure durations ( i . e . , as the regimens move through 1, 4, 9, then finally 28 treatment days the BMDs also increase).

also in 4,078 other papers